How to cite item

Clinical outcomes comparison on the addition of adjuvant radiotherapy to minimally invasive surgery versus adjuvant radiotherapy to open radical hysterectomy in women with cervical cancer: a systematic review

   
@article{TRO10478,
	author = {David Andi Wijaya and Nicolas Daniel Widjanarko and Christian Ambrosius Soeiono and Gulam Gumilar and Bartolomeus Alvin Tjandra},
	title = {Clinical outcomes comparison on the addition of adjuvant radiotherapy to minimally invasive surgery versus adjuvant radiotherapy to open radical hysterectomy in women with cervical cancer: a systematic review},
	journal = {Therapeutic Radiology and Oncology},
	volume = {10},
	number = {0},
	year = {2026},
	keywords = {},
	abstract = {Background: Evidence regarding the oncological safety and effectiveness of combining minimally invasive surgery (MIS) with radiotherapy (RT) as an adjuvant therapy for cervical cancer remains limited. Also, several safety concerns regarding MIS in cervical cancer treatment have been found in a randomized controlled trial conducted in comparison to ORH. This study aims to objectify the recurrence rate and death associated with the different modalities with RT as an adjuvant treatment in International Federation of Gynecology and Obstetrics (FIGO) stage IA–IIB cervical cancer within the included observational studies.Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO. A comprehensive search of PubMed, Scopus, EuropePMC, and Springer was performed to identify observational or interventional studies including women with FIGO stage IA–IIB cervical cancer who received adjuvant radiotherapy following MIS or open radical hysterectomy (ORH). Eligible studies reported survival or recurrence outcomes. Study quality was assessed using the Newcastle-Ottawa Scale (NOS).Results: Six observational studies involving 1,346 patients were included. Across studies, adjuvant radiotherapy was associated with improved local control and recurrence-related outcomes after both MIS and ORH. The benefit appeared more pronounced after MIS, while safety outcomes were inconsistently reported, limiting direct toxicity comparisons.Conclusions: Adjuvant RT plays a role in potentially improving the survival and prognostic factors of patient with cervical cancer FIGO stage IA–IIB who receive both MIS and ORH. However, due to the current limited amount of evidence, a further exploration on the role of adjuvant RT on MIS is needed.},
	issn = {2616-2768},	url = {https://tro.amegroups.org/article/view/10478}
}